Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF

When Recombinant Human VEGF 165 (293-VE) is immobilized at 1 μg/mL (100 μL/well), Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (AVI10460) binds with an ED50 of 4-40 ng/mL.

2 μg/lane of Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (Catalog # AVI10460) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF165 (Catalog # 293-VE) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (Catalog # AVI10460) binds with an ED₅₀ of 4-40 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human VEGFR2/KDR/Flk-1 protein
  

  Human VEGFR2/KDR/Flk-1 (Ala20-Glu764) Accession # AAC16450.1	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: AAC16450.1
• N-terminal Sequence: Ala20
• Structure / Form: Disulfide-linked homodimer, biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 111 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 145-165 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

Vascular endothelial Growth Factor Receptor 2 (VEGFR2), also known as FLK-1, KDR, and CD309, is a type I single-pass membrane receptor. Mature VEGFR2 contains a 745 amino acid extracelluar domain with seven immunoglobulin-like repeats, 21 transmembrane domain and 571 cytoplasmic domain. Within the extracellular domain, human VEGFR2 shares 80% homology with that of mouse and rat. VEGFR2, VEGFR1(Flt-1) and VEGFR3(Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors have almost exclusive expression in the endothelial cells and play essential roles in vasculogenesis and angiogenesis. VEGFR2 is the receptor for VEGF-A, VEGF-C, VEGF-D, and VEGF-E (viral homologs) (1, 2). Monomeric VEGFR2 dimerizes after binding to dimeric ligand and phosphorylate the Tyr in the cytoplasmic domain (3). VEGFR2 can also form heterodimer with VEGFR1 and VEGFR3 (4-6). Alternative splicing isoforms 2 and 3 which lack the transmembrane and cytoplasmic domains function as decoy receptors (7, 8). Targeting the signaling pathways of VEGFR1 and VEGFR2 are potential therapeutic targets for the treatment of inflammation and multiple tumors including breast, gastric, and lung carcinomas (9-12). Cancer immunotherapies using VEGF and VEGFR2 monoclonal antibodies may also be effective in combination with programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) immune checkpoint blockade (13). Our Avi-tag Biotinylated VEGFR2 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Ferra, N. and Davis-Smyth, T. (1997) Endocr. Rev. 18:4.
2. Wise, L.M. et al. (2012) Cell Microbiol. 13:1376.
3. Lepanen, V.M. et al. (2010) Proc. Natl. Acad. Sci. USA 107:2425.
4. Cai, M. et al. (2017) Vascul. Pharmacol. 88:11.
5. Nilsson, I. et al. (2010) EMBO J. 29:1377.
6. Dixelius, J. et al. (2003) J. Biol. Chem. 278:40973.
7. Albuquerque, R.J. et al. (2009) Nat. Med. 15:1023.
8. Jin, P. et al. (2008) Arthritis Res. Ther. 10:R73.
9. Shibuya, M. (2015) Endocr Metab Immune Disord Drug Targets. 15:135.
10. Farzaneh Behelgardi, M. et al. (2020), Mol Biol Rep. 47:2061.
11. Lian, L. et al. (2019) BMC Cancer. 19:183.
12. Hu, C. et al. (2019) Onco. Targets Ther. 12:933.
13. Gao, F. et al. (2020) Curr. Cancer Drug Targets. 20:3.

Bioinformatics

• Uniprot:
  • AAC16450.1()